New approach to adding study drug to chemo for melanoma treatment

February 24, 2011 by Mary Jane Gore

Researchers at Duke University Medical Center have just completed a clinical trial that showed it is possible to study a new combination of drugs against a melanoma recurrence that has not spread beyond a limb. Using a fairly new technique called isolated limb infusion (ILI), they tested an additional drug, called ADH-1, along with a melanoma chemotherapy drug, melphalan. They tried the ADH-1 in an effort to see if this would improve patients’ antitumor responses.

“This technique showed that it is possible to use multiple drugs to treat a melanoma tumor in an isolated limb safely,” said Douglas Tyler, M.D., professor of surgery at Duke University Medical Center. “This technique may also work with other solid tumors identified in limbs.”

The advantage of isolating the affected limb during delivery is that doctors can give many times more chemotherapy than could be given systemwide to a patient, because only the tissues and structures of the limb are affected, as opposed to organ systems.

Although ADH-1 didn’t improve the outcomes of using melphalan alone among the 45 patients, “we think this study is a good demonstration of a much less invasive way to test new compounds or combinations of drugs in certain cancer patients, while avoiding bad side effects,” Tyler said.

Isolated limb infusion is a relatively new technique, used most often in patients, in which a tourniquet is applied to a limb before the infusion of cancer-killing drugs, to keep these drugs from entering the patient’s general blood circulation. The tourniquet is applied for a limited amount of time and the patient is monitored.

“To the best of our knowledge, this phase II trial is the first prospective multicenter isolated limb infusion trial and the first to incorporate a targeted agent in an attempt to enhance the antitumor responses to regional chemotherapy,” Tyler said. He said a next step would be to try a different dosing regimen with ADH-1, because of the promise of earlier findings.

ADH-1 can cause a disruption of N-cadherin adhesion complexes that can lead to changes in intracellular signaling pathways that sensitize tumor cells to melphalan, Tyler said. “We have also showed that ADH-1 can induce changes in blood vessel permeability leading to increased melphalan delivery to tumors.”

More information: The study is being published in the Journal of Clinical Oncology.

Related Stories

Recommended for you

Study prompts new ideas on cancers' origins

December 16, 2017
Rapidly dividing, yet aberrant stem cells are a major source of cancer. But a new study suggests that mature cells also play a key role in initiating cancer—a finding that could upend the way scientists think about the ...

What does hair loss have to teach us about cancer metastasis?

December 15, 2017
Understanding how cancer cells are able to metastasize—migrate from the primary tumor to distant sites in the body—and developing therapies to inhibit this process are the focus of many laboratories around the country. ...

Cancer immunotherapy may work better in patients with specific genes

December 15, 2017
Cancer cells arise when DNA is mutated, and these cells should be recognized as "foreign" by the immune system. However, cancer cells have found ways to evade detection by the immune system.

Scientists pinpoint gene to blame for poorer survival rate in early-onset breast cancer patients

December 15, 2017
A new study led by scientists at the University of Southampton has found that inherited variation in a particular gene may be to blame for the lower survival rate of patients diagnosed with early-onset breast cancer.

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.